Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Oncology Report

• Publication date

  2009-11-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/OR_00000617PMID 19956876
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

  2009cited by this paper
• TNM Classification of Malignant Tumours, 7th Edition

  2009cited by this paper
• Inhibition of mtor in kidney cancer

  2009cited by this paper
• A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies

  2009cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008cited by this paper
• PTEN and p27Kip1 are not downregulated in the majority of renal cell carcinomas--implications for Akt activation.

  2008cited by this paper
• Novel therapeutic options in metastatic renal cancer - review and post ASCO 2007 update.

  2008cited by this paper
• An update on the medical therapy of advanced metastatic renal cell carcinoma

  2008cited by this paper
• Defining the role of mTOR in cancer.

  2007cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• Prognostic relevance of the mTOR pathway in renal cell carcinoma

  2007cited by this paper
• Renal cell carcinoma guideline.

  2007cited by this paper
• Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs

  2005cited by this paper
• Phosphorylation of Mammalian Target of Rapamycin (mTOR) at Ser-2448 Is Mediated by p70S6 Kinase*

  2005cited by this paper
• Rheb binds and regulates the mTOR kinase.

  2005cited by this paper
• Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues.

  2003cited by this paper
• A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.

  2000cited by this paper
• Tissue microarrays for high-throughput molecular profiling of tumor specimens

  1998cited by this paper
• Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate

  1997cited by this paper
• Prognostic significance of morphologic parameters in renal cell carcinoma

  1982cited by this paper

• Glutamine synthetase shields triple-negative breast cancer cells from ferroptosis in metastasis triggered by glutamine deprivation

  2025cites this paper
• Renal cancer: signaling pathways and advances in targeted therapies

  2024cites this paper
• Bisphenol C induces developmental defects in liver and intestine through mTOR signaling in zebrafish (Danio rerio).

  2023cites this paper
• Prognostic significance and tumor-immune infiltration of mTOR in clear cell renal cell carcinoma

  2021influential citation
• The Clinical Kinase Index: A Method to Prioritize Understudied Kinases as Drug Targets for the Treatment of Cancer

  2020cites this paper
• Features of increased malignancy in eosinophilic clear cell renal cell carcinoma

  2020cites this paper
• Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor‐tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma

  2020cites this paper
• Immunohistochemical staining of mTOR, vascular endothelial growth factor, CD34 and microvascular density in clear cell renal cell carcinoma and its correlation with clinicopathological profile of the tumour

  2020cites this paper
• Prognostic significance of PI3K/AKT/ mTOR signaling pathway members in clear cell renal cell carcinoma

  2020cites this paper
• Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status

  2020cites this paper
• The Clinical Kinase Index: Prioritizing Understudied Kinases as Targets for the Treatment of Cancer

  2020cites this paper
• DUSP9 Suppresses Proliferation and Migration of Clear Cell Renal Cell Carcinoma via the mTOR Pathway

  2020cites this paper
• The Identification of Key Gene Expression Signature and Biological Pathways in Metastatic Renal Cell Carcinoma

  2020cites this paper
• Juntendo Medical Journal

  2020cites this paper
• Clinicopathological Study of the Immunohistological Expression of mTOR and Phosphorylated mTOR in Renal Cell Carcinoma

  2020cites this paper
• DUSP9 Suppresses Proliferation and Migration of Clear Cell Renal Cell Carcinoma via the mTOR Pathway

  2020cites this paper
• Inactivation of the AMPK-GATA3-ECHS1 Pathway induces Fatty Acid Synthesis that Promotes Clear Cell Renal Cell Carcinoma Growth.

  2019cites this paper
• mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance

  2018cites this paper
• Speckle-type POZ protein as a diagnostic biomarker in renal cell carcinoma

  2018cites this paper
• Untersuchungen zur Bedeutung zellulärer Regulationsprozesse des Aktivierungsstatus von mTOR und 4E‑BP1 und ihre Auswirkungen auf Tumorgenese und Progression des Prostatakarzinoms - Immunhistochemische Untersuchungen mittels der tissue microarray Technik

  2018influential citation
• Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy

  2016cites this paper
• Combination of mTOR and MAPK Inhibitors—A Potential Way to Treat Renal Cell Carcinoma

  2016cites this paper
• Limited Significance of Activated Akt-Mammalian Target of Rapamycin Signaling Pathway in Prostate Cancer Progression

  2014cites this paper
• Genetic aberrations as the targets of oncology research: Involvement of paraffin-embedded tissues.

  2014cites this paper
• Immunhistochemische Untersuchungen zur Biologie des AKT-Signalwegs bei nichtseminomatösen Hodentumoren

  2014influential citation
• How far is the horizon? From current targets to future drugs in advanced renal cancer

  2014cites this paper
• Putative role of the mTOR/4E-BP1 signaling pathway in the carcinogenesis and progression of gastric cardiac adenocarcinoma.

  2013cites this paper
• Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial

  2013cites this paper
• Loss of pSer2448‐mTOR expression is linked to adverse prognosis and tumor progression in ERG‐fusion‐positive cancers

  2013cites this paper
• Phosphorylated mammalian target of rapamycin is associated with an adverse outcome in oral squamous cell carcinoma.

  2013cites this paper
• α-Lipoic Acid Interaction with Dopamine D2 Receptor-Dependent Activation of the Akt/GSK-3β Signaling Pathway Induced by Antipsychotics: Potential Relevance for the Treatment of Schizophrenia

  2013cites this paper
• Prediction of functional phosphorylation sites by incorporating evolutionary information

  2012cites this paper
• Human Pregnane X Receptor Genotype of the Donor but Not of the Recipient Is a Risk Factor for Delayed Graft Function After Renal Transplantation

  2012cites this paper
• A Functional Variant in the MTOR Promoter Modulates Its Expression and Is Associated with Renal Cell Cancer Risk

  2012cites this paper
• Second-line systemic therapy for the treatment of metastatic renal cell cancer

  2012cites this paper
• mTOR inhibitors: facing new challenges ahead.

  2011cites this paper
• DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma

  2011cites this paper
• Conservation, duplication, and loss of the Tor signaling pathway in the fungal kingdom

  2010cites this paper
• Kinases as targets in the treatment of solid tumors.

  2010cites this paper
• Relational operators for prioritizing candidate biomarkers in high-throughput differential expression data

  2010cites this paper